Rare Genetic Variants Associated with Sudden Cardiac Death
|
By LabMedica International staff writers Posted on 04 Dec 2019 |

Image: Gene Sequencing identifies pathogenic variants in sudden cardiac death versus controls and asymptomatic adults (Photo courtesy of Massachusetts General Hospital)
A recent study has assessed the prevalence of rare pathogenic variants in sudden cardiac death cases versus controls, and the prevalence and clinical importance of such mutations in an asymptomatic adult population.
Sudden cardiac death occurs in around 220,000 adults in the USA annually, the majority of whom have no prior symptoms or cardiovascular diagnosis. Rare pathogenic DNA variants in any of 49 genes can pre-dispose to four important causes of sudden cardiac death: cardiomyopathy, coronary artery disease, inherited arrhythmia syndrome, and aortopathy or aortic dissection.
A large team of scientists working with the Massachusetts General Hospital (Boston, MA, USA) performed whole-exome sequencing in a case-control cohort of 600 adult-onset sudden cardiac death cases and 600 matched controls from 106,098 participants of six prospective cohort studies. Observed DNA sequence variants in any of 49 genes with known association to cardiovascular disease were classified as pathogenic or likely pathogenic by a clinical laboratory geneticist blinded to case status. In an independent population of 4,525 asymptomatic adult participants of a prospective cohort study, the team performed whole-genome sequencing and determined the prevalence of pathogenic or likely pathogenic variants and prospective association with cardiovascular death.
The scientists reported that among the 1,200 sudden cardiac death cases and controls, they identified 5,178 genetic variants and classified 14 as pathogenic or likely pathogenic. These 14 variants were present in 15 individuals, all of whom had experienced sudden cardiac death, corresponding to a pathogenic variant prevalence of 2.5% in cases and 0% in controls. Among the 4,525 participants of the prospective cohort study, 41 (0.9%) carried a pathogenic or likely pathogenic variant and these individuals had 3.24-fold higher risk of cardiovascular death over a median follow-up of 14.3 years.
Amit V. Khera, MD, MSc, an associate director of the Precision Medicine Unit, said, “This really lays the groundwork to say these are important mutations, and what's exciting is if we can identify them, we have treatments for the conditions to which they are tied. We know each of these diseases tends to run in families and there are genetic variants that cause each of these conditions”.
The authors concluded that gene sequencing identifies a pathogenic or likely pathogenic variant in a small but potentially important subset of adults experiencing sudden cardiac death; these variants are present in ∼1% of asymptomatic adults. The study was published on November 18, 2019 in the Journal of the American College of Cardiology.
Related Links:
Massachusetts General Hospital
Sudden cardiac death occurs in around 220,000 adults in the USA annually, the majority of whom have no prior symptoms or cardiovascular diagnosis. Rare pathogenic DNA variants in any of 49 genes can pre-dispose to four important causes of sudden cardiac death: cardiomyopathy, coronary artery disease, inherited arrhythmia syndrome, and aortopathy or aortic dissection.
A large team of scientists working with the Massachusetts General Hospital (Boston, MA, USA) performed whole-exome sequencing in a case-control cohort of 600 adult-onset sudden cardiac death cases and 600 matched controls from 106,098 participants of six prospective cohort studies. Observed DNA sequence variants in any of 49 genes with known association to cardiovascular disease were classified as pathogenic or likely pathogenic by a clinical laboratory geneticist blinded to case status. In an independent population of 4,525 asymptomatic adult participants of a prospective cohort study, the team performed whole-genome sequencing and determined the prevalence of pathogenic or likely pathogenic variants and prospective association with cardiovascular death.
The scientists reported that among the 1,200 sudden cardiac death cases and controls, they identified 5,178 genetic variants and classified 14 as pathogenic or likely pathogenic. These 14 variants were present in 15 individuals, all of whom had experienced sudden cardiac death, corresponding to a pathogenic variant prevalence of 2.5% in cases and 0% in controls. Among the 4,525 participants of the prospective cohort study, 41 (0.9%) carried a pathogenic or likely pathogenic variant and these individuals had 3.24-fold higher risk of cardiovascular death over a median follow-up of 14.3 years.
Amit V. Khera, MD, MSc, an associate director of the Precision Medicine Unit, said, “This really lays the groundwork to say these are important mutations, and what's exciting is if we can identify them, we have treatments for the conditions to which they are tied. We know each of these diseases tends to run in families and there are genetic variants that cause each of these conditions”.
The authors concluded that gene sequencing identifies a pathogenic or likely pathogenic variant in a small but potentially important subset of adults experiencing sudden cardiac death; these variants are present in ∼1% of asymptomatic adults. The study was published on November 18, 2019 in the Journal of the American College of Cardiology.
Related Links:
Massachusetts General Hospital
Latest Molecular Diagnostics News
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
- Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
- Liquid Biopsy Captures Gene Activity Patterns in Small-Cell Lung Cancer
- Genomic Sequencing Identifies Actionable Findings to Guide Rare Disease Management
- Combined Blood Tests Help Clarify Colorectal Cancer Recurrence Risk
- Blood RNA Test May Detect Precursors to Ovarian Cancer
- Microsatellite Instability Test Gains FDA Approval for Immunotherapy Selection
- Blood-Detected Chromosomal Changes May Refine Colorectal Cancer Risk Assessment
- AI Tool Automates Variant Curation and Interpretation for Cancer Whole-Genome Sequencing
- Portable Test Detects Zika and Hepatitis C RNA from Whole Blood
- DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes
- Blood-Based Test May Predict Response Across Rheumatoid Arthritis Drug Classes
- New Research Examines Hi-C Sequencing Across Solid Tumors and Lymphoma
Channels
Clinical Chemistry
view channel
Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read more
Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
Rheumatic heart disease (RHD) causes hundreds of thousands of deaths annually, disproportionately affecting children and young adults in low- and middle-income countries. Early detection remains challenging... Read moreMolecular Diagnostics
view channel
AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more
AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Advances in molecular diagnostics are creating new opportunities to identify inherited diseases earlier, improve the classification of childhood cancers, and track infectious disease outbreaks affecting children.... Read more
Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
Tempus AI (Chicago, IL, USA) will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place November 18–21 in Seoul, South Korea.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







